• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

  • ID: 1322600
  • June 2015
  • 53 pages
  • GlobalData

FEATURED COMPANIES

  • Alkermes, Inc.
  • Ambrx, Inc.
  • ANDRX Corporation
  • Depomed, Inc.
  • DURECT Corporation
  • Nektar Therapeutics
  • MORE

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkermes, Inc.
  • Ambrx, Inc.
  • ANDRX Corporation
  • Depomed, Inc.
  • DURECT Corporation
  • Nektar Therapeutics
  • MORE

List of Tables
List of Figures
Section 1 - About the Company
Flamel Technologies S.A. - Key Facts
Flamel Technologies S.A. - Key Employees
Flamel Technologies S.A. - Key Employee Biographies
Flamel Technologies S.A. - Major Products and Services
Flamel Technologies S.A. - Pharmaceutical Pipeline Products Data
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A. - History
Flamel Technologies S.A. - Company Statement
Flamel Technologies S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Flamel Technologies S.A. - Business Description
Flamel Technologies S.A. - Corporate Strategy
Flamel Technologies S.A. - SWOT Analysis
SWOT Analysis - Overview
Flamel Technologies S.A. - Strengths
Strength - Focused Research and Development Activities
Strength - Polymer-Based Drug Delivery Platforms
Strength - Lead Products
Flamel Technologies S.A. - Weaknesses
Weakness - History of Operating Losses
Weakness - Complete Response Letter
Flamel Technologies S.A. - Opportunities
Opportunity - Need for Novel Delivery Systems
Opportunity - New product Launches
Opportunity - Strategic Divestitures
Flamel Technologies S.A. - Threats
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Threat - Dependence on Limited Customer Base
Flamel Technologies S.A. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Flamel Technologies S.A., Recent Deals Summary
Section 5 – Company’s Recent Developments
May 15, 2015: Flamel Technologies Announces First Quarter Results of Fiscal Year 2015
Apr 07, 2015: Flamel Technologies Announces Departure of Senior Vice President of Business and Corporate Development
Mar 19, 2015: Flamel Technologies Announces Fourth Quarter and Full Year Results of Fiscal Year 2014
Dec 16, 2014: Flamel Technologies Transfers Intangible Property to Irish-Based Subsidiary in Global Reorganization
Dec 15, 2014: Flamel Technologies to Be Included in NASDAQ Biotech Index
Oct 31, 2014: Flamel Technologies Announces Third Quarter Results of Fiscal Year 2014
Sep 29, 2014: Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime Ibuprofen
Jul 29, 2014: Flamel Technologies Announces Second Quarter of Fiscal Year 2014 Results
Jun 16, 2014: Flamel Technologies Receives Class 1 Response Designation for Second NDA
Apr 29, 2014: Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Flamel Technologies S.A., Key Facts
Flamel Technologies S.A., Key Employees
Flamel Technologies S.A., Key Employee Biographies
Flamel Technologies S.A., Major Products and Services
Flamel Technologies S.A., Number of Pipeline Products by Therapy Area
Flamel Technologies S.A., Number of Pipeline Products by Development Stage
Flamel Technologies S.A., Pipeline Products By Therapy Area and Development Phase
Flamel Technologies S.A., History
Flamel Technologies S.A., Subsidiaries
Flamel Technologies S.A., Key Competitors
Flamel Technologies S.A., Ratios based on current share price
Flamel Technologies S.A., Annual Ratios
Flamel Technologies S.A., Interim Ratios
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Flamel Technologies S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A., Performance Chart (2010 - 2014)
Flamel Technologies S.A., Ratio Charts
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015

Note: Product cover images may vary from those shown

Enzon Pharmaceuticals, Inc.
ANDRX Corporation
Ambrx, Inc.
DURECT Corporation
Nektar Therapeutics
Human Genome Sciences, Inc.
Depomed, Inc.
SkyePharma PLC
Alkermes, Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Grifols, S.A. Takeda Pharmaceutical Company Limited Alexion Pharmaceuticals Teva Pharmaceutical Industries Ltd. Endo International Plc. Essilor International S.A.